Tolvaptan in Chinese cirrhotic patients with ascites: A randomized, placebo ‐controlled phase 2 trial

CONCLUSIONTolvaptan at 15 mg/day significantly reduced the body weight and abdominal circumference in patients with liver cirrhosis‐associated ascites. These responses will be confirmed in a phase 3 trial.

Source: Journal of Digestive Diseases - December 1, 2017 Category: Gastroenterology Authors: Yongfeng Wang, Jieting Tang, Tao Han, Huiguo Ding, Weijiang Ye, Maorong Wang, Jun Cheng, Yongping Yang, Chengwei Chen, Qing Xie, Qing Mao, Junqi Niu, Zhenghua Wang, Zhong Wei, Yingxuan Chen, Minde Zeng, Yimin Mao Tags: Original article Source Type: research